CCL5 and pancreatic neoplasm: The downregulation of CCL5 by the immunoregulatory factor 5 (IRF5) mRNA/C–C chemokine ligand 5 (CCL5) siRNA (LPR) nanoparticle combination (LPR@CHG) significantly increased M1-TAMs and modified the immune microenvironment in pancreatic cancer [121].